By Josh White
Date: Tuesday 26 Aug 2025
(Sharecast News) - ValiRx announced a new wholly owned subsidiary Blue Ribbon Bio on Tuesday, to consolidate its prostate cancer assets and accelerate development of its Val201 peptide therapy.
By Josh White
Date: Friday 20 Jun 2025
(Sharecast News) - ValiRx confirmed on Friday that Ambrose Healthcare has exercised its option to license the VAL401 oncology asset, in a deal worth up to £16m plus royalties.
By Josh White
Date: Thursday 03 Apr 2025
(Sharecast News) - ValiRx announced the immediate termination of its letter of intent with TheoremRx on Thursday, ending exclusive negotiations originally set to run until 31 May.
| Currency | UK Pounds |
| Share Price | 0.20p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 0.75 |
| 52 Week Low | 0.19 |
| Volume | 6,161,493 |
| Shares Issued | 742.80m |
| Market Cap | £1.45m |
| RiskGrade | 435 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 15:16 | 750 @ 0.20p |
| 15:08 | 896,863 @ 0.19p |
| 11:09 | 613,138 @ 0.20p |
| 10:27 | 100,000 @ 0.20p |
| 10:06 | 2,500 @ 0.19p |
You are here: research